- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NRAS Mutations in Melanoma
Richard W. Joseph, MD, highlights clinical trial results showing that melanoma patients with NRAS mutations tend to have better response rates to immunotherapy compared with patients with wild-type NRAS. NRAS mutations may be valuable predictors of response in patients with melanoma, suggests Dr Joseph.
Dr Joseph discusses previous research that investigated whether response rates for patients treated with high-dose interleukin-2 varied based on whether the patient had an NRAS mutation, a BRAF mutation, or were wild-type for both NRAS and BRAF. The results showed that patients with NRAS mutations responded better to treatment than patients with BRAF mutations or patients who were wild-type for both NRAS and BRAF. More recent research has demonstrated that patients with NRAS mutations also respond better when treated with other types of immunotherapies, he adds.
Although these results are exciting, there is still no definitive answer as to why melanoma patients with NRAS mutations respond better than patients without such mutations, remarks Dr Joseph. He is hopeful that additional studies will provide additional insight into the role of NRAS mutations in melanoma.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More
